Compositions comprising omega-3 fatty acids, 17-hdha and 18-hepe and methods of using same

Abstract

The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.

1 . A composition, comprising:
 omega-3 fatty acids present in an amount of about 20% to about 99%, by weight, of the composition; and   17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (“17-HDHA”),   4-hydroxy-5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (“4-HDHA”),   7-hydroxy-4Z,8E,10Z,13Z,16Z,19Z-docosahexaenoic acid (“7-HDHA”), and   5S-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid (“5S-HEPE”),   wherein 17-HDHA is present in an amount of about 0.01% to about 1%, by weight, of the composition.   
     
     
         2 . The composition of  claim 1 , wherein the composition is present in a capsule or in an emulsion. 
     
     
         3 . The composition of  claim 1 , wherein the omega-3 fatty acids comprise docosahexaenoic acid (“DHA”) and/or eicosapentaenoic acid (“EPA”). 
     
     
         4 . The composition of  claim 1 , wherein the omega-3 fatty acids are in the form of free fatty acids, esters, phospholipids, mono-glycerides, di-glycerides, tri-glycerides, or mixtures thereof. 
     
     
         5 . The composition of  claim 1 , wherein the omega-3 fatty acids are in the form of ethyl esters. 
     
     
         6 . The composition of  claim 1 , wherein the omega-3 fatty acids are in the form of free fatty acids, esters, mono-glycerides, di-glycerides, tri-glycerides, or mixtures thereof. 
     
     
         7 . The composition of  claim 1 , wherein 17-HDHA, 4-HDHA, 7-HDHA, and/or 5S-HEPE are in the form of free fatty acids, esters, phospholipids, mono-glycerides, di-glycerides, tri-glycerides, or combinations thereof. 
     
     
         8 . The composition of  claim 1 , wherein 17-HDHA, 4-HDHA, 7-HDHA, and/or 5S-HEPE are in the form of ethyl esters. 
     
     
         9 . The composition of  claim 1 , wherein 17-HDHA, 4-HDHA, 7-HDHA, and/or 5S-HEPE are in the form of free fatty acids, esters, mono-glycerides, di-glycerides, tri-glycerides, or mixtures thereof. 
     
     
         10 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.02% to about 1%, by weight, of the composition. 
     
     
         11 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.03% to about 1%, by weight, of the composition. 
     
     
         12 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.04% to about 1%, by weight, of the composition. 
     
     
         13 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.05% to about 1%, by weight, of the composition. 
     
     
         14 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.06% to about 1%, by weight, of the composition. 
     
     
         15 . The composition of  claim 1 , wherein 17-HDHA is present in an amount of about 0.07% to about 1%, by weight, of the composition. 
     
     
         16 . The composition of  claim 1 , further comprising 10S-hydroxy-4Z,7Z,11E, 13Z, 16Z, 19Z-docosahexaenoic acid (“10S-HDHA”) and 11S-hydroxy-4Z,7Z, 9E, 13Z, 16Z, 19Z-docosahexaenoic acid (“11S-HDHA”). 
     
     
         17 . The composition of  claim 1 , further comprising 11-hydroxy-5Z,8Z,12E,14Z,17Z-eicosapentaenoic acid (“11-HEPE”). 
     
     
         18 . A dietary supplement, nutraceutical product, nutritional composition for infant formulae and/or prenatal formulae, pharmaceutical composition, vaccine coadjuvant, chemotherapeutic coadjuvant, or medical food composition comprising the composition of  claim 1 . 
     
     
         19 . A method of treating inflammation, the method comprising administering the composition of  claim 1  to a subject having inflammation. 
     
     
         20 . The method of  claim 19 , wherein the inflammation is associated with at least one disease selected from the group consisting of Alzheimer's disease, neuronal inflammation, infectious diseases, wound healing, asthma, pulmonary inflammation, dermatitis, type 2 diabetes, metabolic syndrome, and obesity.